Aridai Resendiz1, Giulia Martini2, Bruno Sensi3, Rossella Reddavid1, Giulia Marchiori1, Caterina Franco1, Marzia Franceschilli3, Natalia Imperio2, Giuseppe Sica3, Gaya Spolverato2, Maurizio Degiuli4. 1. Department of Oncology, Surgical Oncology and Digestive Surgery Unit, S Luigi University Hospital, University of Turin, Regione Gonzole 10, 10043, Orbassano, Turin, Italy. 2. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. 3. Department of Surgical Science, Minimally Invasive and GI Unit, Tor Vergata University Hospital, Rome, Italy. 4. Department of Oncology, Surgical Oncology and Digestive Surgery Unit, S Luigi University Hospital, University of Turin, Regione Gonzole 10, 10043, Orbassano, Turin, Italy. maurizio.degiuli@unito.it.
Abstract
PURPOSE: The LARS score is an internationally well-accepted questionnaire to assess low anterior resection syndrome, but currently there is no formally validated Italian version. The purpose of this study was to test the reliability and validity of the Italian version among Italian patients submitted to sphincter-sparing surgery for rectal cancer. METHODS: The English version of the LARS score was translated into Italian following the forward-and-back translation process. A total of 147 patients filled out our version. Among them, 40 patients answered the questionnaire twice for the test-retest reliability phase. The validity of the LARS score was tested using convergent and discriminant validity indicators by correlating the EORTC QLQ-C30 and QLQ-CR29 questionnaires. The LARS score capability to differentiate groups of patients with different demographic or clinical features was also assessed. RESULTS: The test-retest reliability was excellent in 87.5% of patients, remained in the same LARS category in both tests. The convergent validity phase showed a relevant relationship of the LARS score with the EORTC domains, which was significant for 7 of 15 EORTC QLQ-C30 subscales, and for 14 of 29 EORTC QLQ-CR29 subscales. The LARS score was able to discriminate patients who received radiotherapy (p = 0.0026), TME vs. PME (p = 0.0060), tumour site at < 10 cm from the anal verge (p = 0.0030) and history of protective stoma (p < 0.0001). CONCLUSION: The Italian version of the LARS score is a valid and reliable tool for measuring LARS in Italian patients after SSS for rectal cancer.
PURPOSE: The LARS score is an internationally well-accepted questionnaire to assess low anterior resection syndrome, but currently there is no formally validated Italian version. The purpose of this study was to test the reliability and validity of the Italian version among Italian patients submitted to sphincter-sparing surgery for rectal cancer. METHODS: The English version of the LARS score was translated into Italian following the forward-and-back translation process. A total of 147 patients filled out our version. Among them, 40 patients answered the questionnaire twice for the test-retest reliability phase. The validity of the LARS score was tested using convergent and discriminant validity indicators by correlating the EORTC QLQ-C30 and QLQ-CR29 questionnaires. The LARS score capability to differentiate groups of patients with different demographic or clinical features was also assessed. RESULTS: The test-retest reliability was excellent in 87.5% of patients, remained in the same LARS category in both tests. The convergent validity phase showed a relevant relationship of the LARS score with the EORTC domains, which was significant for 7 of 15 EORTC QLQ-C30 subscales, and for 14 of 29 EORTC QLQ-CR29 subscales. The LARS score was able to discriminate patients who received radiotherapy (p = 0.0026), TME vs. PME (p = 0.0060), tumour site at < 10 cm from the anal verge (p = 0.0030) and history of protective stoma (p < 0.0001). CONCLUSION: The Italian version of the LARS score is a valid and reliable tool for measuring LARS in Italian patients after SSS for rectal cancer.
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: S Gujral; T Conroy; C Fleissner; O Sezer; P M King; K N L Avery; P Sylvester; M Koller; M A G Sprangers; J M Blazeby Journal: Eur J Cancer Date: 2007-05-22 Impact factor: 9.162
Authors: Veronica De Simone; Francesco Litta; Roberto Persiani; Gianluca Rizzo; Luigi Sofo; Roberta Menghi; Francesco Santullo; Alberto Biondi; Claudio Coco; Franco Sacchetti; Fabio Longo; Miriam Attalla El Halabieh; Rossana Moroni; Carlo Ratto Journal: Front Surg Date: 2022-06-20